Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 oct. 2025 02h45 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines presenterar positiva data från en preklinisk studie med SVF-001 inom kronisk hepatit B och D

STOCKHOLM, 24 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat positiva resultat från en preklinisk studie med bolagets...
24 oct. 2025 02h45 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines presents positive data from a preclinical study of SVF-001 in chronic hepatitis B and D

STOCKHOLM, Sweden, October 24, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented positive results from a preclinical study of its...
09 oct. 2025 13h24 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag PharmNovo får godkännande att inleda en fas 2a-studie med läkemedelskandidaten PN6047 i Spanien

STOCKHOLM, SVERIGE 9 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget PharmNovo fått godkänt av spanska myndigheter att inleda en klinisk fas 2a-studie med...
09 oct. 2025 13h24 HE | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company PharmNovo receives approval to initiate a phase 2a trial of its drug candidate PN6047 in Spain

STOCKHOLM, SWEDEN – October 9, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company PharmNovo has received approval from the Spanish regulatory...
03 oct. 2025 02h30 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Dilafor beviljas patent i USA för tafoxiparin vid initiering av spontan förlossning

STOCKHOLM, 3 oktober 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Dilafor beviljats ett patent i USA som skyddar bolagets läkemedelskandidat tafoxiparin...
03 oct. 2025 02h30 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor

STOCKHOLM, SWEDEN – October 3, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has been granted a patent in the US protecting its drug...
16 sept. 2025 03h05 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag AnaCardio har slutfört rekryteringen i sin fas 2a-studie med läkemedelskandidaten AC01

STOCKHOLM, SVERIGE 16 september 2025 Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört patientrekryteringen i fas 2a-delen av den kliniska...
16 sept. 2025 03h05 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company AnaCardio completes patient recruitment in phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN September 16, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed enrollment in the phase 2a part of its...
04 sept. 2025 02h50 HE | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Umecrine Cognition publicerar data som visar på ihållande effekt av golexanolon i preklinisk Parkinsonmodell

STOCKHOLM, 4 september 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget Umecrine Cognition presenterar data som visar att läkemedelskandidaten golexanolon ger...
04 sept. 2025 02h50 HE | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company Umecrine Cognition publishes data showing sustained effect of golexanolone in a Parkinson’s disease model

STOCKHOLM – September 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has presented data showing that its drug candidate...

Page précédente

Page suivante